- Home
- EPRX vs ZTEK Comparison
EPRX vs ZTEK Comparison
Compare EPRX & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- ZTEK
- Stock Information
- Founded
- EPRX 2011
- ZTEK 2008
- Country
- EPRX Canada
- ZTEK Canada
- Employees
- EPRX N/A
- ZTEK N/A
- Industry
- EPRX
- ZTEK Major Chemicals
- Sector
- EPRX
- ZTEK Industrials
- Exchange
- EPRX NYSE
- ZTEK Nasdaq
- Market Cap
- EPRX 111.1M
- ZTEK 116.6M
- IPO Year
- EPRX N/A
- ZTEK N/A
- Fundamental
- Price
- EPRX $3.33
- ZTEK $1.04
- Analyst Decision
- EPRX Strong Buy
- ZTEK
- Analyst Count
- EPRX 1
- ZTEK 0
- Target Price
- EPRX $9.00
- ZTEK N/A
- AVG Volume (30 Days)
- EPRX 24.6K
- ZTEK 42.0K
- Earning Date
- EPRX 02-07-2025
- ZTEK 02-11-2025
- Dividend Yield
- EPRX N/A
- ZTEK N/A
- EPS Growth
- EPRX N/A
- ZTEK N/A
- EPS
- EPRX N/A
- ZTEK N/A
- Revenue
- EPRX N/A
- ZTEK $29,132.00
- Revenue This Year
- EPRX N/A
- ZTEK N/A
- Revenue Next Year
- EPRX N/A
- ZTEK N/A
- P/E Ratio
- EPRX N/A
- ZTEK N/A
- Revenue Growth
- EPRX N/A
- ZTEK 8.15
- 52 Week Low
- EPRX $2.20
- ZTEK $0.50
- 52 Week High
- EPRX $4.08
- ZTEK $1.59
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- ZTEK 48.31
- Support Level
- EPRX N/A
- ZTEK $1.05
- Resistance Level
- EPRX N/A
- ZTEK $1.16
- Average True Range (ATR)
- EPRX 0.00
- ZTEK 0.08
- MACD
- EPRX 0.00
- ZTEK -0.02
- Stochastic Oscillator
- EPRX 0.00
- ZTEK 16.42
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.